According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.
To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.
Data snapshot as of Q4 2018
Trends: In May, 2018, the FDA granted an additional indication to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone for people with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transport. Via AIS Health.
To read the full Reality Check on Multiple Myeloma treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: